PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aapspharmspringer.comThis journalToc AlertsSubmit OnlineOpen Choice
 
AAPS PharmSciTech. 2003 September; 4(3): 94–100.
Published online 2003 July 9. doi:  10.1208/pt040341
PMCID: PMC2750634

Acid-treated yeast cell wall as a binder displaying function of disintegrant

Abstract

This investigation examined the application of acid-treated yeast cell wall (AYC) as a binder functioning as a disintegrant. Acetylsalicylic acid (ASA) was granulated with AYC, hydroxypropylcellulose (HPC), polyvinylpyrrolidone (PVP), or pullulan (PUL) and compressed into a tablet in the absence of disintegrant. Particle size and angle of repose of the granules, tensile strength, disintegration time, and water absorption behavior of the tablets and ASA release profiles from the tablets were measured. The surface of AYC-granules was observed with a scanning electron microscope. As was the case with the granules of HPC, PVP, or PUL, D50 of the granules of AYC increased with increasing AYC addition percentage, indicating that it is possible to granulate ASA with AYC. Tablets incorporating HPC, PVP, and PUL failed to disintegrate within 30 minutes at all percentages of binder addition because in the case of the HPC, PVP, or PUL tablets in the dissolution medium, water scarcely penetrated into the inner region of the tablet, causing no disintegration. In the case of the AYC tablets, disintegration was not detected at 3% or less of AYC. When AYC was equal to or greater than 5%, AYC tablets disintegrated in approximately 4 minutes and rapid ASA release from the tablets was observed. These results may have been caused by the following. In the case of the AYC 3% granules, ungranulated aspirin powder remained, but in the case of the AYC 5% granules, ASA powder was granulated and covered with AYC. Water absorption was observed initially; however, a plateau was reached in the case of the AYC 3%-tablet. In contrast, in the cases of the AYC 5% and more tablets, water absorption was greater and increased with time. The angle of repose of the AYC 5% granules was 25.7°, which represented high fluidity. The tablets produced by compressing the granules demonstrated sufficient tensile strength greater than 0.8 MPa. The tablets rapidly disintegrated and rapid ASA release was obtained. AYC functioned as a binder at granulation; additionally, AYC served as a disintegrant in the dissolution of drug from the tablets. These results indicate that AYC affords high utility as a unique pharmaceutical additive possessing contrary functions such as binding and disintegration.

Keywords: acid-treated yeast cell wall, pharmaceutical additive, binder, disintegrant, granulation, swelling

Full Text

The Full Text of this article is available as a PDF (426K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
1. Kaneko K, Kanada K, Ouchi K, et al. Control of drug release from granules coated with sodium alginate and calcium lactate through insoluble gel formation. J Pharm Sci Technol. 1999;59:8–16.
2. Watanabe K, Yakou S, Takayama K, Machida Y, Nagai T. Drug release behaviors from hydrogel prepared with water soluble dietary fibers. J Pharm Sci Technol. 1991;51:29–35.
3. Ashford M, Fell J, Atwood D, Sharma H, Woodhead P. Studies on pectin formulation for colonic drug delivery. J Control Release. 1994;30:225–232. doi: 10.1016/0168-3659(94)90028-0. [Cross Ref]
4. Hou W, Miyazaki S, Takada M. Intragastric-floating and sustained-release tablets using chitosan and chitosan hydrochloride. J Pharm Sci Technol. 1991;51:93–99.
5. Kasai T, Eguchi T, Ishiwaki N, Kaneshige J, Ozeki T, Yuasa H. Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive, I: AYC as a novel coating material. Int J Pharm. 2000;204:53–59. doi: 10.1016/S0378-5173(00)00465-8. [PubMed] [Cross Ref]
6. Yuasa H, Kaneshige J, Ozeki T, Kasai T, Eguchi T, Ishiwaki N. Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive, II: effects of curing on the medicine release from AYC-coated tablets. Int J Pharm. 2000;209:69–77. doi: 10.1016/S0378-5173(00)00555-X. [PubMed] [Cross Ref]
7. Yuasa H, Kaneshige J, Ozeki T, Kasai T, Eguchi T, Ishiwaki N. Application of acid-treated yeast cell wall (AYC) as a pharmaceutical additive, III: AYC aqueous coating onto granules and film formation mechanism of AYC. Int J Pharm. 2002;237:15–22. doi: 10.1016/S0378-5173(02)00008-X. [PubMed] [Cross Ref]
8. Yuasa H, Katsuyama H, Ozeki T, et al. Acid-treated yeast cell wall (AYC) as a novel binder. J Pharm Sci Technol. 2002;62:153–160.
9. Northcote DH, Horne RW. The chemical composition and structure of the yeast cell wall. Biochem J. 1952;51:232–236. [PubMed]
10. Fleet GH, Manners DH. Isolation and composition of an alkali-soluble glucan from the cell walls of Ssaccharomyces cerevisiae. J Gen Microbiol. 1976;94:180–192. [PubMed]
11. Lampen JO. External enzymes of yeast: their nature and formation. Antonie Van Leeuwenhoek. 1968;34:1–18. doi: 10.1007/BF02046409. [PubMed] [Cross Ref]
12. Kidby DK, Davies R. Invertase and disulphide bridges in the yeast wall. J Gen Microbiol. 1970;61:327–333. [PubMed]
13. Joneja SK, Harcum WW, Skinner G, Barnum PE, Guo JH. Investigating the fundamental effects of binders on pharmaceutical tablet performance. Drug Dev Ind Pharm. 1999;25:1129–1135. doi: 10.1081/DDC-100102279. [PubMed] [Cross Ref]
14. Salib NN, El-Gamal SA. Application of some polymers in the physicochemical design of tablet formulation. Pharmazie. 1976;31:718–721. [PubMed]
15. Kawaguchi T, Sunada H, Yonezawa Y, et al. Granulation of acetaminophen by a rotating fluidized-bed granulator. Pharm Dev Technol. 2000;5:141–151. doi: 10.1081/PDT-100100529. [PubMed] [Cross Ref]
16. Lipps DM, Salr AM. Characterization of wet granulation process paramaters using response surface methodology, I: top-spray fluidized bed. J Pharm Sci. 1994;83:937–947. doi: 10.1002/jps.2600830705. [PubMed] [Cross Ref]
17. Thiel WJ, Nguyen LT. Fluidized bed granulation of an ordered powder mixture. J Pharm Pharmcol. 1982;34:692–699. [PubMed]
18. Chowhan ZY, Chow YP. Compression properties of granulations made with binders containing different moisture contents. J Pharm Sci. 1981;70:1134–1139. doi: 10.1002/jps.2600701011. [PubMed] [Cross Ref]
19. Meshali M, El-banna HM, El-Sabbagh H. Use of a fractional factorial design to evaluate granulations prepared in a fluidized bed. Pharmazie. 1983;26:323–325. [PubMed]
20. Soyeux P, Delacourte A, Delie B, Lefevre P, Boniface B. Influence and optimisation of operating parameters with a new binder in wet granulation. Eur J Pharm Biopharm. 1998;46:95–103. doi: 10.1016/S0939-6411(97)00162-8. [PubMed] [Cross Ref]
21. Gissinger D, Stamm A. A comparative evaluation of the properties of some tablet disintegrants. Drug Dev Ind Pharm. 1980;6:511–536. doi: 10.3109/03639048009068720. [Cross Ref]
22. Kanig JL, Rudunc EM. The mechanisms of disintegrant action. Pharm Technol. 1984;April:50–63.
23. Dumoulin Y, Clement P, Mateescu MA, Cartiler L. Cross-linked amylase as a binder/disintegrant in compressed tablets. S.T.P. Pharma Sci. 1994;4:329–335.
24. Collin-Beach DP, Hollenbeck RG. Determination of the energy of tablet formation during compression of selected pharmaceutical powders. Int J Pharm. 1983;17:313–324. doi: 10.1016/0378-5173(83)90042-X. [Cross Ref]
25. Christer N, Maria G. Studies on direct compression of tablets. XIII: The effect of some dry binders on the tablet strength of compounds with different fragmentation propensity. Int J Pharm. 1985;23:255–263. doi: 10.1016/0378-5173(85)90154-1. [Cross Ref]

Articles from AAPS PharmSciTech are provided here courtesy of American Association of Pharmaceutical Scientists